ライフサイエンスコーパス: muscarinic antagonist

1 ine methylbromide (a peripherally restricted muscarinic antagonist).

2 f pilocarpine were blocked by scopolamine, a muscarinic antagonist.

3 in 23 minutes after topical application of a muscarinic antagonist.

4 locked by a specific alpha2-antagonist and a muscarinic antagonist.

5 s reversed by administration of nicotinic or muscarinic antagonists.

6 was discovered as a very promising class of muscarinic antagonists.

7 ted side effects requiring co-treatment with muscarinic antagonists.

8 n preceded by HVc injections of nicotinic or muscarinic antagonists.

9 and facilitating synapses was blocked by the muscarinic antagonist, 1-5 microM atropine.

10 y an intrastriatal infusion of a cholinergic muscarinic antagonist, a manipulation that greatly suppr

11 ibe the subsequent lead optimization of both muscarinic antagonist and beta2 agonist activities, thro

12 e strongly attenuated by local infusion of a muscarinic antagonist and weakly attenuated by a nicotin

13 t cholinergic agonists promote REM sleep and muscarinic antagonists and monoamines inhibit REM sleep.

14 l longer acting inhaled beta(2)-agonists and muscarinic antagonists (and combinations) are now in dev

15 roid, long-acting beta2 agonist, long-acting muscarinic antagonist, and leukotriene receptor antagoni

16 esence of TTX but were mostly blocked by the muscarinic antagonist atropine (ATR), and the remainder

17 The muscarinic antagonist atropine and the muscarinic recept

18 ntagonists would worsen pathophysiology, the muscarinic antagonist atropine reduced IIS frequency.

19 uld be blocked by topical application of the muscarinic antagonist atropine to the eye, indicating th

20 tinic antagonist mecamylamine but not by the muscarinic antagonist atropine.

21 ecovery in these animals is inhibited by the muscarinic antagonist atropine.

22 mulation is performed in the presence of the muscarinic antagonist atropine.

23 The muscarinic antagonists atropine, scopolamine, and tropic

24 Second, a muscarinic antagonist (atropine) completely abolished st

25 Both actions were blocked by the muscarinic antagonist, atropine.

26 ntly reduced by pretreatment with the i.c.v. muscarinic antagonist, atropine.

27 Atropine, a muscarinic antagonist, blocked the effects of ACh on Ip

28 antagonized by atropine (a centrally active muscarinic antagonist) but not by scopolamine methylbrom

29 rsus a long-acting beta2-agonist/long-acting muscarinic antagonist combination for exacerbation preve

30 -level acoustic stimulation and suggest that muscarinic antagonists could enhance the resistance of t

31 All muscarinic antagonists currently used as bronchodilating

32 This was tested with the M3-selective muscarinic antagonist darifenacin.

33 Finally, we designed a muscarinic antagonist DART in one iteration, demonstrati

34 PI hydrolysis and the effect was blocked by muscarinic antagonists, demonstrating mediation by musca

35 Each muscarinic antagonist displaced [N-methyl-3H]scopolamine

36 MT-7, a highly selective and irreversible m1 muscarinic antagonist, drastically attenuated this respo

37 er controller approaches include long-acting muscarinic antagonists (eg, tiotropium), and biological

38 combined administration of serotonergic and muscarinic antagonists eliminates hippocampal theta acti

39 iperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improv

40 eta2-agonist (indacaterol) and a long-acting muscarinic antagonist (glycopyrrolate), compared with it

41 cts of vagal stimulation were blocked by the muscarinic antagonist glycopyrronium (5 mg kg(-1)).

42 ) as being the most selective synthetic M(4) muscarinic antagonist identified to date.

43 -daily long-acting beta2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50

44 eep-induction can be completely blocked by a muscarinic antagonist, indicating that the REM sleep-ind

45 pium and ipratropium, a structurally similar muscarinic antagonist, inhibited capsaicin responses in

46 -amplitude GI contractions with nonselective muscarinic antagonists is limited in efficacy due to typ

47 s an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatme

48 Tiotropium is a long acting muscarinic antagonist (LAMA), licensed as triple therapy

49 -adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reduction

50 pes, Oxo-M could be antagonized by 10 microM muscarinic antagonists methoctramine and tropicamide but

51 Longacting muscarinic antagonists might also provide additive benef

52 nity has not been reported for any synthetic muscarinic antagonist, nor for natural occurring M(4) an

53 Simultaneous atropine (muscarinic antagonist) or PD142893 (endothelin antagonis

54 by pertussis toxin, atropine (a nonselective muscarinic antagonist), or methoctramine (a selective M2

55 Therefore, solifenacin and other selective muscarinic antagonists represent new adjunct approaches

56 The muscarinic antagonist scopolamine (10(-6) M) had no sign

57 ycaconitine citrate hydrate (MLA) (20 mM) or muscarinic antagonist scopolamine (40 mM) together with

58 Systemic administration of the muscarinic antagonist scopolamine (50 mg/kg) partially a

59 strated that intra-accumbens infusion of the muscarinic antagonist scopolamine 3 hr before the testin

60 ampal injections (30 microg per side) of the muscarinic antagonist Scopolamine augmented adrenocortic

61 Pretreatment with the muscarinic antagonist scopolamine hydrobromide (1.5-6 mg

62 Furthermore, applying the muscarinic antagonist scopolamine reduced attentional mo

63 he serotonergic antagonist methiothepin, the muscarinic antagonist scopolamine, both drugs, or saline

64 levels and the increases were blocked by the muscarinic antagonist scopolamine.

65 e blunted by preinjury administration of the muscarinic antagonist, scopolamine.

66 Here, we tested the hypothesis that muscarinic antagonists selectively disrupt coupling betw

67 , long-acting beta2-agonist, and long-acting muscarinic antagonist, several of which are now in devel

68 They were prevented by the M1-preferring muscarinic antagonists, telenzepine, pirenzepine, and tr

69 ve activity was reversed completely by every muscarinic antagonist tested, which indicates that they

70 (ICS) (n = 1097), 5 RCTs of the long-acting muscarinic antagonist tiotropium (n = 4592), and 6 RCTs

71 The long acting inhaled muscarinic antagonist tiotropium (Spiriva) improves lung

72 cting bronchodilators, including long-acting muscarinic antagonists, to reduce hyperinflation.

73 is setting occupancy of the receptors with a muscarinic antagonist was without detectable effect on a

74 nic antagonists - and atropine (2 mg/kg) - a muscarinic antagonist - were ineffective against psychos